Cellectis (CLLS) Income from Discontinued Operations (2022 - 2026)
Cellectis' (CLLS) quarterly Income from Discontinued Operations came in at 46000.0 in Q1 2026, up 91.05% quarter-over-quarter from 514000.0 in Q4 2025.
Cellectis (CLLS) Income from Discontinued Operations (2022 - 2026) Analysis & Trends
Cellectis' Income from Discontinued Operations history runs 5 years deep, the most recent figure standing at 46000.0 for Q1 2026.
- On a quarterly basis, Income from Discontinued Operations changed N/A year-over-year to 46000.0 in Q1 2026; TTM through Mar 2026 was 560000.0, a 208.95% decrease from a year earlier, with the FY2025 full-year figure at 514000.0, changed N/A from the prior year.
- Income from Discontinued Operations grew to 46000.0 in Q1 2026 per CLLS's latest filing, from 514000.0 in the prior quarter.
- Across five years, Income from Discontinued Operations topped out at 262000.0 in Q1 2024 and bottomed at 514000.0 in Q4 2025.
- The 5-year median for Income from Discontinued Operations is 66500.0 (2022), against an average of 62125.0.
- Biggest YoY gain for Income from Discontinued Operations was 174.81% in 2024; the steepest drop was 155.66% in 2024.
- Year by year, Income from Discontinued Operations stood at 87000.0 in 2022, then decreased by 21.84% to 106000.0 in 2023, then jumped by 155.66% to 59000.0 in 2024, then slumped by 971.19% to 514000.0 in 2025, then surged by 91.05% to 46000.0 in 2026.
- Per Business Quant, the three latest CLLS Income from Discontinued Operations figures stand at 46000.0 (Q1 2026), 514000.0 (Q4 2025), and 59000.0 (Q3 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | - |
| 10 | Cellectis | 286.65 Mn | 100.99 Mn | - | -46,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46,000.00 |
| Dec 31, 2025 | -514,000.00 |
| Sep 30, 2024 | 59,000.00 |
| Jun 30, 2024 | 193,000.00 |
| Mar 31, 2024 | 262,000.00 |
| Sep 30, 2023 | -106,000.00 |
| Jun 30, 2023 | -258,000.00 |
| Dec 31, 2022 | -87,000.00 |